SCHEDULE 13G/A: BlackRock Discloses 6.7% Passive Stake in Adaptive Biotechnologies Corp

BlackRock, Inc. has filed an Amendment No. 2 to Schedule 13G, disclosing a 6.7% passive beneficial ownership stake in Adaptive Biotechnologies Corp as of March 31, 2025.

Summary

• BlackRock, Inc. has filed an Amendment No. 2 to Schedule 13G, reporting its beneficial ownership in Adaptive Biotechnologies Corp.
• As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 9,940,846 shares of Adaptive Biotechnologies Corp common stock.
• This ownership represents 6.7% of the total outstanding common stock of Adaptive Biotechnologies Corp.
• BlackRock holds sole voting power over 9,721,288 shares and sole dispositive power over 9,940,846 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
• Various BlackRock business units, including BlackRock Advisors, LLC and BlackRock Fund Advisors, contribute to this aggregate ownership, though no single entity's interest is more than five percent of the total outstanding common shares.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing passive ownership, thus it carries a neutral sentiment. While increased institutional ownership can be seen positively, the document itself does not convey explicit positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• The disclosure of a significant passive stake by a major institutional investor like BlackRock can be interpreted as a vote of confidence in Adaptive Biotechnologies Corp's long-term prospects.
• The passive nature of the investment (Rule 13d-1(b)) suggests BlackRock is not seeking to influence control, which can be viewed positively by current management and other shareholders.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Adaptive Biotechnologies Corp's future performance or BlackRock's future investment intentions beyond the passive nature of the holding.

Management Comments

• The filing includes a certification from BlackRock, Inc. stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing reflects a standard disclosure by a major institutional asset manager, BlackRock, Inc., regarding its passive investment holdings in a publicly traded biotechnology company, Adaptive Biotechnologies Corp. Such filings are common for large investment firms that manage significant portfolios across various industries, indicating their positions in companies without necessarily implying active management or strategic influence.

Stakeholder Impact

• For shareholders of Adaptive Biotechnologies Corp: The disclosure of a significant passive stake by a major institutional investor like BlackRock could be interpreted as a vote of confidence, potentially leading to increased investor interest or stability in the stock.
• For Adaptive Biotechnologies Corp management: The passive nature of BlackRock's investment suggests no immediate intent to influence corporate control, allowing management to continue its current strategic direction without direct pressure from this specific shareholder.

Key Dates

Keywords

BlackRock, Adaptive Biotechnologies Corp, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment, 00650F109